Creator: Help Dementia Editorial Team
Published: 2026-04-02T11:04:07

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Second opinion sits at the center of this dementia and brain health question.

When researchers analyzed data from the IDEAS Trial, a landmark study tracking over 16,000 Medicare beneficiaries, they discovered something that challenged standard dementia diagnosis practices: advanced brain imaging altered the initial diagnosis in more than one in three patients (>33%) who presented with mild cognitive impairment or suspected dementia. This wasn’t a minor refinement—it was a fundamental change in how doctors understood what was happening in their patients’ brains. For someone who had been told they were developing Alzheimer’s disease, learning instead that they had a different condition entirely (or no dementia at all) could change everything about their treatment plan, their family’s expectations, and their own future.

The IDEAS Trial, launched in 2016 and published in the Journal of the American Medical Association, was a collaboration between the American College of Radiology, the Alzheimer’s Association, UC San Francisco, Brown University, Virginia Commonwealth University, Washington University School of Medicine, UC Davis, and Kaiser Permanente. It demonstrated that positron emission tomography (PET) scans—which can visualize amyloid and other pathological proteins in the brain—were far more valuable than expected. The results rippled through the medical community because they proved that a second opinion, when backed by advanced imaging, wasn’t just helpful; it was often essential. This article examines why second opinions matter so much in dementia diagnosis, what the research actually shows about diagnostic changes, and what patients and families should know about seeking that second look.

Why Dementia Diagnoses Get Changed So Often in Second Opinions
What Changed in Patient Management After Second Opinions and Imaging
The Scope of Misdiagnosis in Dementia: What Current Research Shows
How to Approach Getting a Second Opinion for Dementia
When Second Opinions Matter Most—And the Limitations to Understand
Real-World Impact: How Diagnostic Changes Affected Patient Outcomes
The Future of Dementia Diagnosis: Beyond Second Opinions
Conclusion

Why Dementia Diagnoses Get Changed So Often in Second Opinions

Dementia diagnosis has long been one of medicine’s trickier challenges. Unlike a blood test for diabetes or an X-ray that shows a broken bone, dementia diagnosis traditionally relied on cognitive testing, patient history, and clinical judgment. Two neurologists examining the same patient could reasonably reach different conclusions. The IDEAS Trial revealed just how often this happens: amyloid PET imaging changed diagnoses in more than 33% of cases, meaning roughly one in three patients with suspected dementia got a fundamentally different answer after imaging. The reasons for these changes are revealing.

Some patients thought to have Alzheimer’s disease—the kind driven by amyloid and tau protein buildup—actually showed little to no amyloid burden on PET scans. Others diagnosed with mild cognitive impairment actually had advanced amyloid pathology that warranted more aggressive monitoring. Still others had been incorrectly labeled as having dementia when their symptoms were actually caused by something else entirely: medication side effects, depression, sleep apnea, vitamin B12 deficiency, or other treatable conditions. A second opinion with imaging could sort these scenarios clearly. The comparison is striking: while neurologists relying on clinical assessment alone might diagnose Alzheimer’s disease with reasonable confidence, PET imaging provides objective evidence of whether the hallmark proteins are actually present. It’s the difference between a doctor saying “your symptoms sound like Alzheimer’s” and being able to say “your brain imaging shows Alzheimer’s-related pathology.” That certainty changes everything about what comes next.

Why Dementia Diagnoses Get Changed So Often in Second Opinions

What Changed in Patient Management After Second Opinions and Imaging

The diagnostic changes in the IDEAS Trial translated into real clinical consequences. The research showed that PET scan results altered medical management—the medications prescribed, counseling approaches, therapy recommendations, and monitoring frequency—in approximately two-thirds of cases (67%). That’s more than double what the researchers had predicted before the study began. In other words, a second opinion didn’t just change the label on the diagnosis; it changed how doctors actually treated the patient. Consider a concrete example: a 72-year-old woman presents to her primary care doctor with memory problems. The doctor diagnoses her with mild Alzheimer’s disease and recommends an amyloid-targeting medication along with cognitive training. She seeks a second opinion and gets a PET scan.

The scan shows minimal amyloid but striking tau pathology in a pattern characteristic of primary age-related tauopathy (PART)—a different disease entirely, with a different prognosis. The new neurologist decides the amyloid medication isn’t appropriate for her specific condition, adjusts her management plan, and has a very different conversation about what to expect. Without the second opinion and imaging, she might have spent years on an ineffective medication. However, advanced imaging like PET scans isn’t universally available or always practical. Insurance coverage for these scans varies, they require specialized PET imaging centers, and they’re not designed for every patient with memory problems. The IDEAS Trial enrolled Medicare beneficiaries with specific inclusion criteria—those with mild cognitive impairment or dementia of uncertain cause. For a patient with obvious, severe dementia and clear cognitive decline over years, additional imaging might confirm what’s already clinically obvious without meaningfully changing management. The value of a second opinion with imaging is greatest in the diagnostic gray zone: when the cause isn’t entirely clear, or when the clinical picture is atypical.

The Scope of Misdiagnosis in Dementia: What Current Research Shows

The IDEAS Trial findings weren’t an isolated observation. Broader research into diagnostic accuracy in dementia paints a concerning picture. Recent research published in 2025 examining diagnostic errors in suspected frontotemporal dementia found that 70% of patients suspected of having this disease actually did not have it. They had been misdiagnosed. For patients and families already dealing with the anxiety of a dementia diagnosis, the stakes of getting it right are enormous. Across all second-opinion scenarios—not just brain imaging, but when patients seek another expert opinion for any reason—the picture is consistent.

Approximately 88% of patients who pursue second opinions for dementia concerns receive a new or refined diagnosis. This doesn’t necessarily mean the first doctor was incompetent; it reflects the genuine complexity of dementia diagnosis and the value of a fresh set of eyes, different clinical experience, and sometimes access to testing that wasn’t available at the first encounter. A family doctor might be excellent at managing hypertension and diabetes but less experienced with the nuances of dementia. A second opinion from a neurologist or geriatrician with specialized dementia expertise can add crucial clarity. The experience of diagnostic refinement is particularly important early in cognitive decline, when the difference between normal aging, mild cognitive impairment, and early dementia can be subtle. Getting this right affects whether a patient qualifies for certain medications, how family members plan for the future, and what supportive services make sense to put in place.

The Scope of Misdiagnosis in Dementia: What Current Research Shows

How to Approach Getting a Second Opinion for Dementia

Seeking a second opinion requires thoughtfulness. It’s not about questioning your doctor’s intelligence or insulting their judgment; it’s about getting the clearest possible picture of what’s actually happening. The first step is often to ask your primary care doctor for a referral to a neurologist or geriatrician with dementia expertise. Many doctors welcome second opinions, especially in complex diagnostic situations, and can suggest specialists they trust. When you see a second-opinion specialist, bring all relevant medical records—cognitive testing results, brain imaging (MRI, CT scans), blood work, medication lists, and detailed notes about when symptoms started and how they’ve changed. This allows the new doctor to see the full picture rather than starting from scratch.

If the first evaluation included neuropsychological testing (detailed cognitive testing by a specialist psychologist), this is especially valuable to share, as it provides objective data about which cognitive domains are affected. The second-opinion doctor may repeat some tests to confirm findings or may order new tests (like PET imaging) that weren’t done before. Be prepared for the possibility that the second opinion might confirm the first diagnosis rather than change it. This isn’t a “failure” of the second opinion; it’s valuable confirmation. Alternatively, the second opinion might refine the diagnosis—from “possible Alzheimer’s disease” to “probable Alzheimer’s disease with some vascular components”—adding nuance rather than completely changing the picture. Both scenarios are clinically useful. The tradeoff is that seeking a second opinion takes time, may involve travel, and could trigger additional testing costs (though many insurance plans cover second opinions), but the diagnostic clarity it provides is often worth the investment.

When Second Opinions Matter Most—And the Limitations to Understand

Second opinions with advanced imaging are most valuable when the diagnosis is genuinely uncertain. The IDEAS Trial specifically enrolled patients with “dementia of uncertain cause”—people whose symptoms suggested dementia but whose diagnosis wasn’t clear-cut. In these situations, a second opinion can be transformative. If, however, a patient already has clear-cut, unambiguous dementia with obvious progression over years, multiple prior evaluations confirming the diagnosis, and brain imaging already done showing Alzheimer’s pathology, another second opinion is unlikely to change management meaningfully. One important limitation: access to specialized imaging and dementia expertise varies enormously by geography and insurance status. The IDEAS Trial involved Medicare beneficiaries and academic medical centers—patients with insurance coverage and proximity to specialized services.

Not everyone has easy access to PET imaging centers or dementia specialists. Rural patients, uninsured patients, and those with limited transportation face real barriers to obtaining second opinions with advanced imaging. Understanding what imaging is available to you and whether your insurance covers it is an essential first step. Another limitation concerns the natural history of undiagnosed conditions. Some people with cognitive symptoms who seem like dementia candidates might actually have depression, early Parkinson’s disease, or cognitive effects of sleep apnea—conditions that show up differently on specialized testing but that improve with treatment of the underlying cause. A second opinion can help identify these scenarios, but it requires someone to think creatively and not anchor too heavily on the “dementia” label from the first evaluation.

When Second Opinions Matter Most—And the Limitations to Understand

Real-World Impact: How Diagnostic Changes Affected Patient Outcomes

The IDEAS Trial didn’t just count how many diagnoses changed; it tracked how these changes affected what doctors actually recommended. When PET imaging revealed that a patient thought to have Alzheimer’s disease actually had minimal amyloid, doctors often stopped recommending (or reconsidered) disease-modifying amyloid-targeting medications. When imaging showed unexpected high tau burden or other pathology, doctors intensified monitoring or adjusted medications. These management changes happened in roughly two-thirds of cases—a profound shift in clinical decision-making.

For patients and families, these changes often felt liberating or, sometimes, dismaying, depending on what was discovered. A person diagnosed with Alzheimer’s disease who learns via second opinion that they have very minimal amyloid burden might learn they have less immediate cognitive decline to expect, or that the disease progression might be slower. Conversely, someone who thought they had simple age-related memory issues might learn they have significant amyloid pathology and need closer monitoring. The point is that management becomes aligned with biology rather than guesswork. Medications, counseling, family planning, and supportive services can all be tailored to what’s actually happening in the brain rather than what seemed most likely clinically.

The Future of Dementia Diagnosis: Beyond Second Opinions

The IDEAS Trial data underscores a broader shift in dementia medicine toward biomarker-based diagnosis—using objective biological evidence rather than symptoms alone. Blood biomarkers for amyloid, tau, and phosphorylated tau are now available and are becoming more accessible and affordable. In the future, a patient with memory concerns might receive a blood test as a first-line evaluation, with imaging reserved for cases where blood work is unclear or additional detail is needed. This could democratize access to reliable dementia diagnosis, making second opinions with biomarker confirmation possible outside major academic centers.

This shift also means that the “standard” initial evaluation for memory concerns may evolve. Rather than relying on cognitive testing and clinical judgment alone, more primary care doctors may routinely order blood biomarker testing as a screening tool, identifying who truly has Alzheimer’s-related pathology versus other causes of cognitive symptoms. When that happens, the need for second opinions might diminish simply because the first opinion would be based on objective evidence from the start. Until then, seeking a second opinion—especially if diagnostic uncertainty remains after an initial evaluation—remains a reasonable and often clarifying step.

Conclusion

The IDEAS Trial’s finding that more than one in three patients received altered diagnoses after PET imaging demonstrates that dementia diagnosis, as currently practiced, is neither simple nor always certain. A second opinion, particularly when supported by advanced brain imaging or biomarker testing, can fundamentally change how patients understand their condition and how doctors manage their care. For someone navigating a new dementia diagnosis, the investment in seeking that second opinion—whether from a dementia specialist, through additional imaging, or both—is often one of the most important medical decisions they can make. If you or a family member has received a dementia diagnosis and something about it doesn’t sit quite right, or if the diagnosis was surprising given how few symptoms are present, pursuing a second opinion is reasonable and appropriate.

Start by asking your primary care doctor for a referral to a neurologist or geriatrician with dementia expertise. Bring all medical records and testing results. Be open to what you learn, whether it confirms, refines, or changes the initial diagnosis. The clarity that comes from a thorough second evaluation—particularly early in cognitive decline—can guide treatment decisions, family planning, and expectations for years to come.